Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GentiBio, Inc.
AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease
The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001 which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.